Fortress Biotech (FBIO) & Its Competitors Critical Survey

Fortress Biotech (NASDAQ:FBIO) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Fortress Biotech to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, earnings, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fortress Biotech and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1	1	2	0	2.25
Fortress Biotech Competitors	7819	13779	25784	1035	2.41

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 745.77%. As a group, “Pharmaceuticals” companies have a potential upside of 23.79%. Given Fortress Biotech’s higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than its competitors.

Profitability

This table compares Fortress Biotech and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Fortress Biotech Competitors	-2,393.16%	-220.83%	-16.11%

Risk and Volatility

Fortress Biotech has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Fortress Biotech’s competitors have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Insider & Institutional Ownership

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fortress Biotech and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Fortress Biotech	$63.26 million	$6.82 million	0.76
Fortress Biotech Competitors	$5.37 billion	$3.23 billion	555.01

Fortress Biotech’s competitors have higher revenue and earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Fortress Biotech beats its competitors on 7 of the 13 factors compared.

About Fortress Biotech

Fortress Biotech, Inc. (NASDAQ: FBIO) is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiary companies and strategic partnerships. Its research and development activities have focused on areas including dermatology, immunology, oncology, rare diseases and other conditions with significant unmet medical needs. The company’s portfolio has included dermatology products such as ZILXI, a topical minocycline foam for the treatment of inflammatory lesions associated with rosacea, and Qbrexza, a topical treatment for primary axillary hyperhidrosis.